Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2016 Sep;82(3):814-22.
doi: 10.1111/bcp.13006. Epub 2016 Jun 17.

Respiratory effect of beta-blocker eye drops in asthma: population-based study and meta-analysis of clinical trials

Daniel R Morales  1 , Tobias Dreischulte  2 , Brian J Lipworth  3 , Peter T Donnan  4 , Cathy Jackson  5 , Bruce Guthrie  1
Affiliations
Meta-Analysis

Respiratory effect of beta-blocker eye drops in asthma: population-based study and meta-analysis of clinical trials

Daniel R Morales et al. Br J Clin Pharmacol. 2016 Sep.

Abstract

Aims: To measure the prevalence of beta-blocker eye drop prescribing and respiratory effect of ocular beta-blocker administration in people with asthma.

Methods: We measured the prevalence of ocular beta-blocker prescribing in people with asthma and ocular hypertension, and performed a nested case-control study (NCCS) measuring risk of moderate exacerbations (rescue steroids in primary care) and severe exacerbations (asthma hospitalization) using linked data from the UK Clinical Practice Research Datalink. We then performed a systematic review and meta-analysis of clinical trials evaluating changes in lung function following ocular beta-blocker administration in people with asthma.

Results: From 2000 to 2012, the prevalence of non-selective and selective beta-blocker eye drop prescribing in people with asthma and ocular hypertension fell from 23.0% to 13.4% and from 10.5% to 0.9% respectively. In the NCCS, the relative incidence (IRR) of moderate exacerbations increased significantly with acute non-selective beta-blocker eye drop exposure (IRR 4.83, 95% CI 1.56-14.94) but not with chronic exposure. In the meta-analysis, acute non-selective beta-blocker eye drop exposure caused significant mean falls in FEV1 of -10.9% (95% CI -14.9 to -6.9), and falls in FEV1 of ≥20% affecting one in three. Corresponding values for selective beta-blockers in people sensitive to ocular non-selective beta-blockers was -6.3% (95% CI -11.7 to -0.8), and a non-significant increase in falls in FEV1 of ≥20%.

Conclusion: Non-selective beta-blocker eye drops significantly affect lung function and increase asthma morbidity but are still frequently prescribed to people with asthma and ocular hypertension despite safer agents being available.

Keywords: asthma; beta-blocker; drug safety; glaucoma; meta-analysis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Prevalence of beta‐blocker eye drop prescribing among people with active asthma and ocular hypertension. formula image Any non‐selective beta‐blocker formula image Timolol. formula image Selective beta blockers (betaxolol). formula image Other non‐selective beta‐blocker (levobunolol, carteolol, metipranolol)
Figure 2
Figure 2
Mean percentage change in FEV1 following acute non‐selective and selective beta‐blocker eye drop exposure. For figure 3 ‐ Fall in FEV1 of 15% or greater following acute non‐selective and selective beta‐blocker eye drop exposure
Figure 3
Figure 3
Falls in FEV1 of 15% or greater following acute beta‐blocker eye drop exposure
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. British Thoracic Society Scottish Intercollegiate Guidelines Network . British guideline on the management of asthma. Thorax 2008; 63: iv1–iv121. - PubMed
    1. Global Initiative for Asthma . Global strategy for asthma management and prevention. Available at http://wwwginasthmaorg/ (last accessed 31 September 2014).
    1. American Academy of Ophthalmology Preferred Practice Patterns . Primary Open‐Angle Glaucoma PPP‐2010 [online]. Available at http://one.aao.org/preferred‐practice‐pattern/primary‐openangle‐glaucoma... (last accessed 17 December 2014).
    1. Morales DR, Jackson C, Lipworth BJ, Donnan PT, Guthrie B. Adverse respiratory effect of acute β‐blocker exposure in asthma: a systematic review and meta‐analysis of randomized controlled trials. Chest 2014; 145: 779–86. - PubMed
    1. Frishman WH, Fuksbrumer MS, Tannenbaum M. Topical ophthalmic beta‐adrenergic blockade for the treatment of glaucoma and ocular hypertension. J Clin Pharmacol 1994; 34: 795–803. - PubMed

MeSH terms

Substances